Selective androgen receptor modulators

OPKO Health to Report Second Quarter 2019 Financial Results on August 7, 2019

Retrieved on: 
Thursday, August 1, 2019
Selective androgen receptor modulators, OPKO Health, SARM, Oxyntomodulin, Organic compounds, Chemistry, Nitriles, Functional groups, Tertiary alcohols, Organofluorides

The replay can be accessed for a period of time on OPKOs website at OPKO 2Q19 Results Conference Call .

Key Points: 
  • The replay can be accessed for a period of time on OPKOs website at OPKO 2Q19 Results Conference Call .
  • OPKO Health is a diversified healthcare company.
  • OPK88003, a once-weekly oxyntomodulin for type 2 diabetes and obesity recently reported positive data from a Phase 2 clinical trial.
  • OPK88004, a SARM (selective androgen receptor modulator) is currently being studied for various potential indications.

OPKO Health and OPKO's CEO and Chairman, Dr. Phillip Frost, Announce Proposed Resolution of SEC Action

Retrieved on: 
Thursday, December 27, 2018
RTT, Andrology, Benign prostatic hyperplasia, Men's Health, SARM, Private Securities Litigation Reform Act, Selective androgen receptor modulators

"We have reached agreement with the SEC that will end a potentially expensive, contentious and time-consuming litigation and I am happy that we can focus on an exciting and productive 2019 for OPKO Health," said Dr.

Key Points: 
  • "We have reached agreement with the SEC that will end a potentially expensive, contentious and time-consuming litigation and I am happy that we can focus on an exciting and productive 2019 for OPKO Health," said Dr.
  • Without admitting or denying the SEC's allegations, OPKO agreed to an injunction from certain violations of the Securities Exchange Act of 1934 (the "Exchange Act"); a $100,000 penalty; and will perform certain undertakings related to the Exchange Act.
  • OPK88004, a SARM (Selective Androgen Receptor Modulator) for treating BPH (Benign Prostatic Hypertrophy), urinary incontinence, and other conditions, is in clinical trials.
  • We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.